Feature | Stents | November 08, 2017

OrbusNeich Combo Dual-therapy Stent Noninferior Vs. Xience Stent in HARMONEE Trial

One-year results from the study were presented at TCT 2017

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Mitchell W. Krucoff M.D., FACC, FAHA, FSCAI, professor of medicine/cardiology, Duke University Medical Center, director, cardiovascular devices unit, Duke Clinical Research Institute, presenting the Japan-USA HARMONEE trial results during a press conference at TCT 2017. 

How the OrbusNeich Combo stent works.

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report investigations session at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrate that the OrbusNeich Combo Dual-therapy Stent (DTS) compares favorably to the market-leading Abbott Xience stent for treating patients with significant ischemic heart disease. 

The Japan-United States of America Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s Combo StEnt (HARMONEE) is a pivotal (Shonin, Japan) registration study being conducted to demonstrate the effectiveness of the combined endothelial progenitor cell capture and drug-eluting stent (COMBO) compared to the Xience stent in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome. The results showed that the overall incidence of the primary endpoint target vessel failure (TVF) was lower than the original estimated 9 percent, with 7 percent in the Combo group vs. 4.2 percent in the Xience group at 12 months, thereby meeting the non-inferiority requirement (P = 0.020).[1]
“Achieving non-inferiority in TVF compared to the best-in-class current DES, with the addition of superior surrogate measures of site healing by COMBO in this randomized study, represents the opening of an exciting new chapter in percutaneous coronary intervention device design targeting enhanced safety and effectiveness for patients with coronary artery disease,” said Principal Investigator Mitchell Krucoff, M.D., Ph.D., FACC, FAHA, FSCAI, professor of medicine/cardiology, Duke University Medical Center, director, cardiovascular devices unit, Duke Clinical Research Institute, Durham, N.C.
Kaplan-Meier curves revealed that target vessel revascularization (TVR) events driven by the one-year protocol re-catheterization were notable in both stent groups, despite the use of fractional flow reserve (FFR) to mitigate such event spikes. The TVF odds ratio of Combo versus imputed bare-metal stent (BMS) was 0.673 and did not meet the pre-specified assay sensitivity, but the comparison was underpowered due to the low TVF rates (4.2 vs. predicted 9 percent). Combo was superior to imputed BMS with respect to angiographic in stent (P<0.001) and in segment late-loss (P=0.003) at 12 months.
An independent quantitative coronary arteriography core laboratory reported in stent late loss at one year of Combo vs. Xience of 0.293 mm vs. 0.219 mm and in segment late loss of 0.229 mm vs. 0.220 mm respectively. Additionally, the angiographic in stent restenosis of Combo vs. Xience was 1.3 vs. 2.6 percent and in segment restenosis was 2.5 vs. 3.9 percent.
Optical coherence tomography (OCT) at 12 months revealed significantly better healthy tissue strut coverage (thickness >40 micron in patients with normal FFR) with Combo vs. Xience (91.56 vs. 74.82 percent; P<0.001). Also, the qualitative appraisal of the neo-intima showed more homogeneous tissue with Combo vs. Xience (81.2 vs. 68.8 percent). “OCT observations suggest an active mechanistic role of EPC technology including superior healthy tissue strut coverage with Combo vs. the everolimus-eluting stent, and more qualitatively homogeneous neointimal tissue with Combo,” Krucoff explained.
The results from HARMONEE build further evidence for Combo and help to support OrbusNeich’s planned application for approval in Japan and to meet the feasibility trial requirements in the U.S.

About the HARMONEE Study

The HARMONEE study [NCT02073565] was conducted in 50 hospitals in Japan and the USA, enrolling a total of 572 patients, who were randomized to receive a COMBO stent or a Xience stent in a 1:1 fashion. The protocol defined primary clinical endpoint of the HARMONEE study was target vessel failure (TVF), a composite of cardiac mortality, myocardial infarction, or ischemic target vessel revascularization within one year of post index treatment. Fractional flow reserve (FFR) was used as an objective quantitative indicator for ischemia. OCT assessments were performed after six and 12 months in subsets of patients in order to provide mechanistic insights into the healing patterns in both groups, with attention to factors likely to be affected by the EPC capture technology. All patients were followed up at 12 months with quantitative coronary angiography (QCA), including FFR.
For more information: www.OrbusNeich.com

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations


1. Krucoff M, Saito S. “HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES with a Luminal CD34+ Antibody Coating vs a Durable Polymer-Based DES in Patients with Coronary Artery Disease.” Oral presentation at the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium, Oct. 30, 2017.

Related Content

SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.,

Major mergers in interventional cardiology.

Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.


Figure 2. Serial optical coherence tomography findings of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Videos | Cath Lab | March 27, 2018
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional cardio
American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Overlay Init